Video

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

Author(s):

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

C. Parker Gibbs Jr, MD, Eugene L. Jewett professor of Orthopaedic Surgery, chief medical officer, University of Florida Health Shands Hospital, division chief of Musculoskeletal Oncology, University of Florida College of Medicine, discusses how to test for p16 and p21 in patients with osteosarcoma.

The cell cycle checkpoint regulator proteins p16 and p21 have shown promise as predictive biomarkers with the ability to give insight into a patient’s potential response to treatment for osteosarcoma, explains Gibbs. To test for p16 and p21, a surgical or needle biopsy is performed when a patient presents with osteosarcoma to learn about the diagnosis and the best way to treat.

After the tissue is obtained, it is stained via immunohistochemistry for p16 or p21. From there, the amount of expression the proteins emit can determine the relative risk of metastatic disease or death, concludes Gibbs.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity